Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: Long-term changes due to drug interactions and their association with clinical outcomes

被引：7

作者：

Shimomura H. ^{[1
]}

Andachi S. ^{[1
]}

Aono T. ^{[1
]}

Kigure A. ^{[1
]}

Yamamoto Y. ^{[1
]}

Miyajima A. ^{[1
]}

Hirota T. ^{[1
]}

Imanaka K. ^{[2
]}

Majima T. ^{[3
]}

Masuyama H. ^{[3
]}

Tatsumi K. ^{[4
]}

Aoyama T. ^{[1
]}

机构：

[1] Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba

[2] Chemotherapy Research Institute, Kaken Hospital, Department of Pharmacy, 6-1-14 Konodai, Ichikawa, Chiba

[3] Chemotherapy Research Institute, Kaken Hospital, Department of Respiratory medicine, 6-1-14 Konodai, Ichikawa, Chiba

[4] Graduate School of Medicine, Chiba University, Department of Respirology, 1-8-1 Inohana, Chuo-ku, Chiba

来源：

Journal of Pharmaceutical Health Care and Sciences | / 1卷 / 1期

关键词：

6 beta-hydroxycortisol to cortisol ratio; Clarithromycin; Clinical efficacy; CYP3A4; Mycobacterium avium complex; Rifampicin; Serum concentration;

D O I：

10.1186/s40780-015-0029-0

中图分类号：

学科分类号：

摘要：

Background: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions. To date, however, there has been no report that investigates the long-term relationship between the drug concentrations, CYP3A4 activity, and clinical outcomes. Our aim was to investigate the time course of the drug levels in long-term treatment of subjects with pulmonary MAC disease, and examine the correlation of these concentrations with CYP3A4 activity and clinical outcomes. Methods: Urine and blood samples from nine outpatients with pulmonary MAC disease were collected on days 1, 15, and 29 (for four subjects, sample collections were continued on days 57, 85, 113, 141, 169, 225, 281, 337, and 365). Serum drug concentrations and urinary levels of endogenous cortisol (F) and 6 beta-hydroxycortisol (6βOHF), the metabolite of F by CYP3A4, were measured, and evaluated 6βOHF/F ratio as a CYP3A4 activity marker. In addition, the clinical outcomes of 4 subjects were evaluated based on examination of sputum cultures and chest images. Results: The mean 6βOHF/F ratio increased from 2.63 ± 0.85 (n = 9) on the first day to 6.96 ± 1.35 on day 15 and maintained a level more than double initial value thereafter. The serum CAM concentration decreased dramatically from an initial 2.28 ± 0.61 μg/mL to 0.73 ± 0.23 μg/mL on day 15. In contrast, the serum concentration of 14-hydroxy-CAM (M-5), the major metabolite of CAM, increased 2.4-fold by day 15. Thereafter, both CAM and M-5 concentrations remained constant until day 365. The explanation for the low levels of serum CAM in pulmonary MAC disease patients is that RFP-mediated CYP3A4 induction reached a maximum by day 15 and remained high thereafter. Sputum cultures of three of four subjects converted to negative, but relapse occurred in all three cases. Conclusions: Our study demonstrated that serum CAM concentrations in pulmonary MAC disease patients were continuously low because of RFP-mediated CYP3A4 induction, which may be responsible for the unsatisfactory clinical outcomes. © 2015 Shimomura et al.

引用

共 35 条

[1] Yamamoto M., Kuze F., Sakatani M., Saito H., Shimoide H., Soejima R., Et al., The clinical study of clarithromycin for pulmonary Mycobacterium avium -intracellulare complex infection, Kekkaku, 72, pp. 1-7, (1997)
[2] Wallace R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T., Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients, Am J Respir Crit Care Med, 153, pp. 1766-1772, (1996)
[3] Sato K., Ebe T., A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease, Kekkaku, 75, pp. 471-476, (2000)
[4] Yamamoto F., Harada S., Mitsuyama T., Harada Y., Kitahara Y., Yoshida M., Et al., Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin, Jpn J Antibiot, 57, pp. 124-133, (2004)
[5] Taki H., Ogawa K., Nakagawa T., Kashima K., Tarumi O., Saitou Y., Et al., Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection, Kekkaku, 82, pp. 641-646, (2007)
[6] Wallace R.J., Brown B.A., Griffith D.E., Girard W., Tanaka K., Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection, J Infect Dis, 171, pp. 747-750, (1995)
[7] Tran J.Q., Kovacs S.J., McIntosh T.S., Davis H.M., Martin D.E., Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction, J Clin Pharmacol, 39, pp. 487-494, (1999)
[8] Wakasugi H., Yano I., Ito T., Hashida T., Futami T., Nohara R., Sasayama S., Inui K., Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein, Clin Pharmacol Ther, 64, pp. 123-128, (1998)
[9] Mayhew B.S., Jones D.R., Hall S.D., An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation, Drug Metab Dispos, 28, pp. 1031-1037, (2000)
[10] Alffenaar J.W., Nienhuis W.A., Velde F., Zuur A.T., Wessels A.M., Almeida D., Et al., Phamacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection, Antimicrob Agents Chemother, 54, pp. 3878-3883, (2010)

← 1 2 3 4 →